{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T17:58:13Z","timestamp":1768413493291,"version":"3.49.0"},"reference-count":40,"publisher":"American Society of Hematology","issue":"21","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2010,5,27]]},"abstract":"<jats:p>Histone hypoacetylation occurs in many cancers and inhibition of histone deacetylation is a promising approach to modulate these epigenetic changes. Our laboratory previously demonstrated that the histone deacetylase inhibitors (HDACis) vorinostat and AR-42 reduced the viability of a canine malignant mast cell line. The purpose of this study was to further investigate the mechanisms of pan-HDAC inhibition in normal and malignant mast cells. Mouse and canine malignant mast cell lines expressing various Kit mutations, normal canine mast cells, and primary canine malignant mast cells were treated with AR-42 (a novel HDACi) and effects on cell viability, cycling, and signaling were evaluated. Treatment with AR-42 induced growth inhibition, cell- cycle arrest, apoptosis, and activation of caspases-3\/7. AR-42 promoted hyperacetylation of H3, H4, and alpha-tubulin, and up-regulation of p21. Down-regulation of Kit occurred after AR-42 treatment via inhibition of Kit transcription. Disassociation between Kit and heat shock protein 90 (HSP90) and up-regulation of HSP70 were observed after AR-42 treatment, suggesting potential loss of HSP90 chaperone function. Lastly, AR-42 down-regulated the expression of p-Akt, total Akt, phosphorylated STAT3\/5 (pSTAT3\/5), and total STAT3\/5. In summary, AR-42 exhibits in vitro and ex vivo biologic activity against malignant mast cells, representing a promising therapeutic approach for malignant mast cell disease.<\/jats:p>","DOI":"10.1182\/blood-2009-07-231985","type":"journal-article","created":{"date-parts":[[2010,3,17]],"date-time":"2010-03-17T01:55:42Z","timestamp":1268790942000},"page":"4217-4225","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":67,"title":["AR-42, a novel HDAC inhibitor, exhibits biologic activity against malignant mast cell lines via down-regulation of constitutively activated Kit"],"prefix":"10.1182","volume":"115","author":[{"given":"Tzu-Yin","family":"Lin","sequence":"first","affiliation":[{"name":"Department of Veterinary Biosciences,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joelle","family":"Fenger","sequence":"additional","affiliation":[{"name":"Department of Veterinary Clinical Sciences, College of Veterinary Medicine, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sridhar","family":"Murahari","sequence":"additional","affiliation":[{"name":"Department of Veterinary Clinical Sciences, College of Veterinary Medicine, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Misty D.","family":"Bear","sequence":"additional","affiliation":[{"name":"Department of Veterinary Biosciences,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel K.","family":"Kulp","sequence":"additional","affiliation":[{"name":"Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dasheng","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Shih","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William C.","family":"Kisseberth","sequence":"additional","affiliation":[{"name":"Department of Veterinary Clinical Sciences, College of Veterinary Medicine, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheryl A.","family":"London","sequence":"additional","affiliation":[{"name":"Department of Veterinary Biosciences,"},{"name":"Department of Veterinary Clinical Sciences, College of Veterinary Medicine, and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2019111903275142100_B1","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/978-1-4020-6554-5_13","article-title":"Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis.","volume":"615","author":"Shankar","year":"2008","journal-title":"Adv Exp Med Biol"},{"issue":"3","key":"2019111903275142100_B2","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s00253-007-0912-1","article-title":"Histone deacetylase inhibitors\u2013turning epigenic mechanisms of gene regulation into tools of therapeutic intervention in malignant and other diseases.","volume":"75","author":"Riester","year":"2007","journal-title":"Appl Microbiol Biotechnol"},{"issue":"3","key":"2019111903275142100_B3","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00253-007-0911-2","article-title":"Histone deacetylases: an important class of cellular regulators with a variety of functions.","volume":"75","author":"Hildmann","year":"2007","journal-title":"Appl Microbiol Biotechnol"},{"issue":"7","key":"2019111903275142100_B4","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s12094-008-0221-x","article-title":"Histone deacetylase inhibitors: mechanism of action and therapeutic use in cancer.","volume":"10","author":"Martinez-Iglesias","year":"2008","journal-title":"Clin Transl Oncol"},{"issue":"29","key":"2019111903275142100_B5","doi-asserted-by":"crossref","first-page":"26729","DOI":"10.1074\/jbc.C500186200","article-title":"Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.","volume":"280","author":"Bali","year":"2005","journal-title":"J Biol Chem"},{"issue":"17","key":"2019111903275142100_B6","doi-asserted-by":"crossref","first-page":"6941","DOI":"10.1158\/0008-5472.CAN-08-4004","article-title":"Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors.","volume":"69","author":"M\u00fchlenberg","year":"2009","journal-title":"Cancer Res"},{"issue":"1","key":"2019111903275142100_B7","first-page":"169","article-title":"The histone deacetylase inhibitor suberoylanilide hydroxamic acid down-regulates expression levels of Bcr-abl, c-Myc and HDAC3 in chronic myeloid leukemia cell lines.","volume":"15","author":"Xu","year":"2005","journal-title":"Int J Mol Med"},{"issue":"16","key":"2019111903275142100_B8","doi-asserted-by":"crossref","first-page":"4882","DOI":"10.1158\/1078-0432.CCR-06-3093","article-title":"Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90.","volume":"13","author":"Fiskus","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2019111903275142100_B9","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1158\/1541-7786.MCR-07-0330","article-title":"Inhibition of histone deacetylases promotes ubiquitin-dependent proteasomal degradation of DNA methyltransferase 1 in human breast cancer cells.","volume":"6","author":"Zhou","year":"2008","journal-title":"Mol Cancer Res"},{"issue":"2","key":"2019111903275142100_B10","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1159\/000101711","article-title":"Mastocytosis: state of the art.","volume":"74","author":"Horny","year":"2007","journal-title":"Pathobiology"},{"issue":"3","key":"2019111903275142100_B11","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0195-5616(03)00003-2","article-title":"Mast cell tumors in the dog.","volume":"33","author":"London","year":"2003","journal-title":"Vet Clin North Am Small Anim Pract"},{"issue":"5","key":"2019111903275142100_B12","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1046\/j.1365-2141.2003.04575.x","article-title":"Diagnosis and treatment of systemic mastocytosis: state of the art.","volume":"122","author":"Valent","year":"2003","journal-title":"Br J Haematol"},{"issue":"12","key":"2019111903275142100_B13","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.2460\/ajvr.2002.63.1718","article-title":"Prevalence and importance of internal tandem duplications in exons 11 and 12 of c-kit in mast cell tumors of dogs.","volume":"63","author":"Downing","year":"2002","journal-title":"Am J Vet Res"},{"issue":"5","key":"2019111903275142100_B14","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1354\/vp.39-5-529","article-title":"Mutations in the juxtamembrane domain of c-KIT are associated with higher grade mast cell tumors in dogs.","volume":"39","author":"Zemke","year":"2002","journal-title":"Vet Pathol"},{"issue":"2","key":"2019111903275142100_B15","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/cncr.21996","article-title":"Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial.","volume":"107","author":"Droogendijk","year":"2006","journal-title":"Cancer"},{"issue":"11","key":"2019111903275142100_B16","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.1158\/1078-0432.CCR-08-1860","article-title":"Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision.","volume":"15","author":"London","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2019111903275142100_B17","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1182\/blood-2003-07-2477","article-title":"17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells.","volume":"103","author":"Fumo","year":"2004","journal-title":"Blood"},{"issue":"10","key":"2019111903275142100_B18","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.exphem.2008.05.001","article-title":"The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors.","volume":"36","author":"Lin","year":"2008","journal-title":"Exp Hematol"},{"issue":"10","key":"2019111903275142100_B19","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1158\/0008-5472.CAN-08-0203","article-title":"OSU-HDAC42, a histone deacetylase inhibitor, blocks prostate tumor progression in the transgenic adenocarcinoma of the mouse prostate model.","volume":"68","author":"Sargeant","year":"2008","journal-title":"Cancer Res"},{"issue":"17","key":"2019111903275142100_B20","doi-asserted-by":"crossref","first-page":"5199","DOI":"10.1158\/1078-0432.CCR-06-0429","article-title":"Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer.","volume":"12","author":"Kulp","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2019111903275142100_B21","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1002\/hep.21804","article-title":"Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma.","volume":"46","author":"Lu","year":"2007","journal-title":"Hepatology"},{"issue":"7","key":"2019111903275142100_B22","doi-asserted-by":"crossref","first-page":"938","DOI":"10.2460\/ajvr.69.7.938","article-title":"Evaluation of the effects of histone deacetylase inhibitors on cells from canine cancer cell lines.","volume":"69","author":"Kisseberth","year":"2008","journal-title":"Am J Vet Res"},{"issue":"17","key":"2019111903275142100_B23","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1021\/jm0503749","article-title":"Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors.","volume":"48","author":"Lu","year":"2005","journal-title":"J Med Chem"},{"issue":"1\u20132","key":"2019111903275142100_B24","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.vetimm.2006.03.024","article-title":"Generation and characterization of bone marrow-derived cultured canine mast cells.","volume":"113","author":"Lin","year":"2006","journal-title":"Vet Immunol Immunopathol"},{"issue":"4","key":"2019111903275142100_B25","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method.","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"issue":"2","key":"2019111903275142100_B26","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1182\/blood-2001-12-0350","article-title":"Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors.","volume":"100","author":"Liao","year":"2002","journal-title":"Blood"},{"issue":"4","key":"2019111903275142100_B27","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0301-472X(98)00075-7","article-title":"Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit.","volume":"27","author":"London","year":"1999","journal-title":"Exp Hematol"},{"issue":"9","key":"2019111903275142100_B28","doi-asserted-by":"crossref","first-page":"5528","DOI":"10.4049\/jimmunol.162.9.5528","article-title":"Mast cell expression of gelatinases A and B is regulated by kit ligand and TGF-beta.","volume":"162","author":"Fang","year":"1999","journal-title":"J Immunol"},{"key":"2019111903275142100_B29","first-page":"1","article-title":"The kit ligand, stem cell factor.","volume":"55","author":"Galli","year":"1994","journal-title":"Adv Immunol"},{"issue":"3\u20134","key":"2019111903275142100_B30","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.vetimm.2006.09.001","article-title":"A functional comparison of canine and murine bone marrow derived cultured mast cells.","volume":"114","author":"Lin","year":"2006","journal-title":"Vet Immunol Immunopathol"},{"issue":"5","key":"2019111903275142100_B31","first-page":"1431","article-title":"Trichostatin A induces apoptosis of p815 mastocytoma cells in histone acetylation- and mitochondria-dependent fashion.","volume":"25","author":"Yee","year":"2004","journal-title":"Int J Oncol"},{"issue":"5","key":"2019111903275142100_B32","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1182\/blood.V99.5.1741","article-title":"The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors: kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations.","volume":"99","author":"Ma","year":"2002","journal-title":"Blood"},{"issue":"2","key":"2019111903275142100_B33","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nsmb0207-90","article-title":"The cellular world according to Hsp90.","volume":"14","author":"Richter","year":"2007","journal-title":"Nat Struct Mol Biol"},{"key":"2019111903275142100_B34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10254-003-0021-1","article-title":"Hsp70 and Hsp90: a relay team for protein folding.","volume":"151","author":"Wegele","year":"2004","journal-title":"Rev Physiol Biochem Pharmacol"},{"issue":"4","key":"2019111903275142100_B35","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.bbrc.2007.03.076","article-title":"FK228 inhibits Hsp90 chaperone function in K562 cells via hyperacetylation of Hsp70.","volume":"356","author":"Wang","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"2019111903275142100_B36","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1471-2407-9-81","article-title":"Characterization of STAT3 activation and expression in canine and human osteosarcoma.","volume":"9","author":"Fossey","year":"2009","journal-title":"BMC Cancer"},{"issue":"2","key":"2019111903275142100_B37","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood-2005-11-4639","article-title":"Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells.","volume":"108","author":"Fiskus","year":"2006","journal-title":"Blood"},{"issue":"4","key":"2019111903275142100_B38","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1124\/mol.104.007831","article-title":"Cotreatment with suberanoylanilide hydroxamic acid and 17-allylamino 17-demethoxygeldanamycin synergistically induces apoptosis in Bcr-Abl+ Cells sensitive and resistant to STI571 (imatinib mesylate) in association with down-regulation of Bcr-Abl, abrogation of signal transducer and activator of transcription 5 activity, and Bax conformational change.","volume":"67","author":"Rahmani","year":"2005","journal-title":"Mol Pharmacol"},{"issue":"4","key":"2019111903275142100_B39","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1182\/blood-2004-09-3413","article-title":"Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.","volume":"105","author":"George","year":"2005","journal-title":"Blood"},{"issue":"pt 8","key":"2019111903275142100_B40","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1242\/jcs.03431","article-title":"HDAC6 deacetylation of tubulin modulates dynamics of cellular adhesions.","volume":"120","author":"Tran","year":"2007","journal-title":"J Cell Sci"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/115\/21\/4217\/1488004\/zh802110004217.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/115\/21\/4217\/1488004\/zh802110004217.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T01:06:16Z","timestamp":1685495176000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/115\/21\/4217\/133746\/AR42-a-novel-HDAC-inhibitor-exhibits-biologic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5,27]]},"references-count":40,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2010,5,27]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2009-07-231985","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5,27]]}}}